Who are Norepinephrine intravenous infusion's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Norepinephrine (10 µg boluses), Continuous infusion of Norepinephrine, Northera, METYROSINE, Demser, Dopamine Hydrochloride.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/norepinephrine-intravenous-infusion.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Norepinephrine intravenous infusion — Competitive Intelligence Brief

Norepinephrine intravenous infusion (Norepinephrine intravenous infusion) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Catecholamine; sympathomimetic amine. Area: Cardiovascular; Critical Care.

marketed Catecholamine; sympathomimetic amine Alpha-1 adrenergic receptor; beta-1 adrenergic receptor Cardiovascular; Critical Care Small molecule Live · refreshed every 30 min

Target snapshot

Norepinephrine intravenous infusion (Norepinephrine intravenous infusion) — University of Sao Paulo. Norepinephrine is a catecholamine that binds to alpha and beta adrenergic receptors to increase blood pressure and heart rate.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Norepinephrine intravenous infusion TARGET	Norepinephrine intravenous infusion	University of Sao Paulo	marketed	Catecholamine; sympathomimetic amine	Alpha-1 adrenergic receptor; beta-1 adrenergic receptor
Norepinephrine (10 µg boluses)	Norepinephrine (10 µg boluses)	Hopital Charles Nicolle	marketed	Catecholamine; sympathomimetic amine	Alpha-1 adrenergic receptor; Beta-1 adrenergic receptor
Continuous infusion of Norepinephrine	Continuous infusion of Norepinephrine	Hassan II University	marketed	Catecholamine; sympathomimetic amine	Alpha-1 adrenergic receptor; Beta-1 adrenergic receptor
Northera	DROXIDOPA	Lundbeck Na Ltd	marketed	Catecholamine	Muscarinic acetylcholine receptor M1	2014-01-01
METYROSINE	METYROSINE		marketed	Catecholamine Synthesis Inhibitor [EPC]		1979-01-01
Demser	metirosine	Aton Pharma Vpna	marketed	Catecholamine Synthesis Inhibitor [EPC]	Tyrosine 3-monooxygenase	1979-01-01
Dopamine Hydrochloride	DOPAMINE		marketed	Catecholamine	D(1A) dopamine receptor	1974-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Catecholamine; sympathomimetic amine class)

Hassan II University · 1 drug in this class
Hopital Charles Nicolle · 1 drug in this class
University of California, Davis · 1 drug in this class
University of Louisville · 1 drug in this class
University of Sao Paulo · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Norepinephrine intravenous infusion — Competitive Intelligence Brief. https://druglandscape.com/ci/norepinephrine-intravenous-infusion. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab